The $50,000 Cure Problem: Why the US Can’t Do What India Already Did | Andy Holt & Phil Vanek
Andy Holt is the Chief Commercial Officer at Viralgen Vector Core, a company specializing in the contract manufacturing of AAV gene therapies. A self-described “really bad molecular biologist” who moved to the commercial side, Andy has spent 18 years in cell and gene therapy, including a stint as VP at AskBio before its acquisition by Bayer. His quote on the wall at Viralgen’s facility in Spain: “Science is magic that works.